Ipilimumab - CISMeF

Preferred Label : Ipilimumab;

NCIt synonyms : Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody; MDX-CTLA4; Ipilimumab Biosimilar CS1002;

NCIt related terms : MDX-010;

NCIt definition : A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.;

Alternative definition : NCI-GLOSS: A monoclonal antibody being studied in the treatment of certain types of cancer. Ipilimumab is made in the laboratory and binds to the molecule CTLA-4 on T cells (a type of white blood cell). Ipilimumab may block CTLA-4 and help the immune system kill cancer cells.;

UNII : 6T8C155666;

CAS number : 477202-00-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 477202-00-9 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Yervoy;

Molecule name : MDX-010; BMS-734016;

NSC code : 732442; 720801;

Codes from synonyms : CDR0000535555; CDR0000438727; 279;

Details

Origin ID

C2654;

UMLS CUI

C1367202;

Automatic exact mappings (from CISMeF team)
- Ipilimumab [ICD-11 Extension code]
- Ipilimumab [MeSH concept]
- MDX-CTLA-4 [MeSH concept]
CISMeF manual mappings
- Ipilimumab (substance) [SNOMED CT concept]
See also inter- (CISMeF)
- Product containing ipilimumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Ipilimumab [MeSH Descriptor]
- Ipilimumab (substance) [SNOMED CT concept]
- Product containing ipilimumab (medicinal product) [SNOMED CT concept]
- ipilimumab [ATC Code]
- ipilimumab [International Nonproprietary Name]
Validated automatic mappings to BTNT
- ipilimumab [ATC Code]
chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Cytotoxic T-Lymphocyte Protein 4 [NCIt concept]
is_component_of_chemotherapy_regimen
- Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody/Interleukin-2 [NCIt concept]
- Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody/Sargramostim [NCIt concept]
- Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody/gp100 antigen/MART-1 antigen/Montanide ISA-51/tyrosinase peptide [NCIt concept]
- Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody/gp100 antigen/Montanide ISA-51 [NCIt concept]
- Carboplatin/Ipilimumab/Nivolumab/Paclitaxel Regimen [NCIt concept]
- Carboplatin/Ipilimumab/Nivolumab/Pemetrexed Regimen [NCIt concept]
- Cisplatin/Ipilimumab/Nivolumab/Pemetrexed Regimen [NCIt concept]
- High-dose Ipilimumab Regimen [NCIt concept]
- Ipilimumab Regimen [NCIt concept]
- Ipilimumab/Nivolumab Followed by Nivolumab Regimen [NCIt concept]
- Ipilimumab/Nivolumab Regimen [NCIt concept]
- Low-dose Ipilimumab/Pembrolizumab Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients